Diabetes

CV Outcomes in Diabetes

Risk reduction with antihyperglycaemic therapies
 

Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).

The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.

CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.

Close X
Other videos you might like

Section Advisor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

Recent Videos

Broadcast

ACC 2020 Wrap Up: An Analysis of the Late-breaking Trials

Nicolas M Van Mieghem, Joost Daemen,

Broadcast

Treating Calcium With Shockwave IVL – the Impact of Disrupt CADIII on…

Holger Nef, Kambis Mashayekhi, Miroslaw Ferenc, et al

Video

ESC 2020: The THEMIS-PAD Trial

Marc P Bonaca,

Video

Wrap-up of AHA 2019: An Analysis of the Late-breaking Trials

Nicolas M Van Mieghem, Joost Daemen,

Video

ACC 2019: DECLARE TIMI 58

Marc P Bonaca,

Video

ESC 2018: CAMELLIA-TIMI 61

Erin A Bohula,